552 related articles for article (PubMed ID: 16860852)
1. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Bell J; Brady MF; Young RC; Lage J; Walker JL; Look KY; Rose GS; Spirtos NM;
Gynecol Oncol; 2006 Sep; 102(3):432-9. PubMed ID: 16860852
[TBL] [Abstract][Full Text] [Related]
2. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
4. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
[TBL] [Abstract][Full Text] [Related]
5. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
6. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
8. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.
Brown JV; Rettenmaier MA; Dillman RA; Birk CL; Culkin K; Micha JP
Gynecol Oncol; 1998 Feb; 68(2):166-8. PubMed ID: 9514805
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
10. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.
Young RC
Semin Oncol; 2000 Jun; 27(3 Suppl 7):8-10. PubMed ID: 10952120
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
Coleman RL; Bagnell KG; Townley PM
Cancer J Sci Am; 1997; 3(4):246-53. PubMed ID: 9263631
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Spriggs DR; Brady MF; Vaccarello L; Clarke-Pearson DL; Burger RA; Mannel R; Boggess JF; Lee RB; Hanly M
J Clin Oncol; 2007 Oct; 25(28):4466-71. PubMed ID: 17906207
[TBL] [Abstract][Full Text] [Related]
16. A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Bamias A; Bamia C; Karadimou A; Soupos N; Zagouri F; Rodolakis A; Haidopoulos D; Vlahos G; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2011; 81(5-6):365-71. PubMed ID: 22248920
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
[TBL] [Abstract][Full Text] [Related]
18. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S
Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and carboplatin as outpatient therapy for stage III and IV epithelial ovarian cancer.
Balbi GC; Menditto A; Calabria G; Musone R; Di Prisco L; Cassese E; Balbi C; Cardone A
Panminerva Med; 2001 Dec; 43(4):263-5. PubMed ID: 11677421
[TBL] [Abstract][Full Text] [Related]
20. Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
Markman M
Gynecol Oncol; 2007 Apr; 105(1):279-80; author reply 280-1. PubMed ID: 17291570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
